Curcumin-based nanoformulations to target breast cancer: current trends and challenges

2021 ◽  
Vol 06 ◽  
Author(s):  
Adnan Badran ◽  
Joelle Mesmar ◽  
Nadine Wehbe ◽  
Riham El Kurdi ◽  
Digambara Patra ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Treatment ◽  
Therapeutic Potential ◽  
Low Cost ◽  
Folk Medicine ◽  
Research Area ◽  
Delivery Systems ◽  
Treatment Modalities ◽  
Anticancer Efficacy ◽  
Future Direction

: Breast cancer remains one of the most common cancers in women worldwide, and despite significant improvements in treatment modalities, the prognosis of this cancer is still poor. Herbs and plant extracts have been associated with various health benefits, and traditional folk medicine is still receiving great interest among patients as proven by accumulated records, tolerable side effects of herbal compounds compared to their synthetic counterparts, and low cost. Curcumin is a polyphenol identified as the main active ingredient in turmeric and has been used in the treatment of various diseases and ailments. Additionally, the pharmacological activities of curcumin on many cancers have been investigated substantially due to its ability to regulate many signaling pathways involved in cancer tumorigenesis and metastasis. However, the low solubility and bioavailability of curcumin limit its benefits, urging the need for new curcumin formulations and delivery systems. Nanotechnology has been widely publicized in cancer treatment not only to overcome the limitations of poorly soluble and physiologically unstable compounds but also to improve the delivery of the drug to the diseased site and cellular uptake. In this review, we summarized the main anti-tumor effect of curcumin and its mode of action on breast cancer and focused on the anticancer efficacy of various and recent curcumin nanoformulations and delivery systems. Such nanotechnological systems could pave the way to address a new future direction in this research area, enhancing the therapeutic potential of curcumin in the treatment of breast cancer. In the next few years, there will be more focus on developing curcumin-based materials for breast cancer treatment.

Role of Phytochemicals in the Treatment of Breast Cancer: Natural Swords battling Cancer Cells

2021 ◽  
Vol 16 ◽  
Author(s):  
Rajni Sawanny ◽  
Sheersha Pramanik ◽  
Unnati Agarwal
Keyword(s):  
Breast Cancer ◽  
Molecular Mechanisms ◽  
Low Cost ◽  
Epigallocatechin Gallate ◽  
Cancer Therapeutics ◽  
Treatment Modalities ◽  
Breast Cancer Patients ◽  
Scientific Validity ◽  
Phytochemical Study ◽  
Treat Breast Cancer

: Breast cancer is the most common type of malignancy among ladies (around 30% of newly diagnosed patients every year). To date, various modern treatment modalities for breast cancer, such as radiotherapy, surgical method, hormonal therapy, and chemotherapeutic drug utilisation, are available. However, adverse drug reactions, therapeutic resistance, metastasis, or cancer reoccurrence chances remain the primary causes of mortality for breast cancer patients. To overcome all the potential drawbacks, we need to investigate novel techniques and strategies previously not considered and treat breast cancer effectively with safety and efficacy. For centuries, we utilise phytochemicals to treat various diseases because of their safety, low-cost & least or no side effects. Recently, naturally produced phytochemicals gain immense attention as potential breast cancer therapeutics because of their ideal characteristics; for instance, they operate via modulating molecular pathways associated with cancer growth and progression. The primary mechanism involves inhibition of cell proliferation, angiogenesis, migration, invasion, increasing anti-oxidant status, initiation of the arrest of the cell cycle, and apoptosis. Remedial viability gets effectively enhanced when phytochemicals work as adjuvants with chemotherapeutic drugs. This comprehensive review revolves around the latest chemopreventive, chemotherapeutic, and chemoprotective treatments with their molecular mechanisms to treat breast cancer by utilising phytochemicals such as vinca alkaloids, resveratrol, curcumin, paclitaxel, silibinin, quercetin, genistein and epigallocatechin gallate. The authors wish to extend the field of phytochemical study for its scientific validity and its druggability.

Therapeutic Potential of Lymphoid Infiltrates in Breast Cancer

2021 ◽  
Vol 28 ◽  
Author(s):  
Xiao-Yang Chen ◽  
Puay Hoon Tan
Keyword(s):  
Breast Cancer ◽  
Immune Response ◽  
Immune System ◽  
Therapeutic Potential ◽  
Antibody Therapy ◽  
Tumour Microenvironment ◽  
Current Treatment ◽  
Adoptive Cell Transfer ◽  
Treatment Modalities ◽  
Patient Specific

: Despite diagnostic and therapeutic advances in breast cancer, it remains the most frequently diagnosed malignancy in females, with the highest cancer-related mortality rate in women globally. With an improved understanding of the complex interactions between breast cancer and the immune system, immunotherapy has shown great potential in clinical management, potentially adding to current treatment modalities. These immunotherapeutic approaches include adoptive cell transfer therapy, cancer vaccination, monoclonal antibody therapy, and oncolytic virus therapy. Depending on the immune cells and cytokines present, the tumour microenvironment (TME) can be immunosuppressive or favourable for mounting an immune response. Effector lymphocytes play an essential role during an anticancer immune response, but their activities can be suppressed by the hostile TME. Many studies have made good progress in the modulation of the immune response to allow the identification and elimination of tumour cells. However, the efficacy of these immunotherapies is patient-specific and highly dependent on the immunological profile of the tumour and its TME. This review will give an overview of breast cancer, the immune system as well as their complex relationship. Strategies and approaches that can harness the potential of immunotherapy that engages lymphocytes in the treatment of breast cancer, along with their current challenges, will also be discussed.

scholarly journals A Review on Chitosan’s Uses as Biomaterial: Tissue Engineering, Drug Delivery Systems and Cancer Treatment

Materials ◽  
2020 ◽  
Vol 13 (21) ◽  
pp. 4995 ◽  
Author(s):  
Rayssa de Sousa Victor ◽  
Adillys Marcelo da Cunha Santos ◽  
Bianca Viana de Sousa ◽  
Gelmires de Araújo Neves ◽  
Lisiane Navarro de Lima Santana ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Tissue Engineering ◽  
Metal Ions ◽  
Cancer Treatment ◽  
Drug Delivery Systems ◽  
Therapeutic Potential ◽  
Delivery Systems ◽  
Amino Groups ◽  
New Information ◽  
Acidic Conditions

Chitosan, derived from chitin, is a biopolymer consisting of arbitrarily distributed β-(1-4)-linked D-glucosamine and N-acetyl-D-glucosamine that exhibits outstanding properties— biocompatibility, biodegradability, non-toxicity, antibacterial activity, the capacity to form films, and chelating of metal ions. Most of these peculiar properties are attributed to the presence of free protonable amino groups along the chitosan backbone, which also gives it solubility in acidic conditions. Moreover, this biopolymer can also be physically modified, thereby presenting a variety of forms to be developed. Consequently, this polysaccharide is used in various fields, such as tissue engineering, drug delivery systems, and cancer treatment. In this sense, this review aims to gather the state-of-the-art concerning this polysaccharide when used as a biomaterial, providing information about its characteristics, chemical modifications, and applications. We present the most relevant and new information about this polysaccharide-based biomaterial’s applications in distinct fields and also the ability of chitosan and its various derivatives to selectively permeate through the cancer cell membranes and exhibit anticancer activity, and the possibility of adding several therapeutic metal ions as a strategy to improve the therapeutic potential of this polymer.

Exploration of the Therapeutic Potential of the Antiestrogen RU 58668 in Breast Cancer Treatment

1995 ◽  
Vol 761 (1) ◽  
pp. 164-175 ◽  
Author(s):  
P. VELDE ◽  
F. NIQUE ◽  
J. BRËMAUD ◽  
M-C. HAMEAU ◽  
D. PHILIBERT ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Treatment ◽  
Therapeutic Potential ◽  
Breast Cancer Treatment

scholarly journals Recent advances of curcumin and its analogues in breast cancer prevention and treatment

RSC Advances ◽  
2015 ◽  
Vol 5 (92) ◽  
pp. 75575-75588 ◽  
Author(s):  
Charlotta D. Mock ◽  
Brian C. Jordan ◽  
Chelliah Selvam
Keyword(s):  
Breast Cancer ◽  
Cancer Treatment ◽  
Cancer Prevention ◽  
Breast Cancer Treatment ◽  
Delivery Systems ◽  
Breast Cancer Prevention ◽  
Curcumin Analogues ◽  
Prevention And Treatment ◽  
Recent Developments ◽  
Novel Delivery Systems

This review focuses on recent developments in the use of curcumin, curcumin analogues, and novel delivery systems as a preventive and therapeutic method for breast cancer treatment.

scholarly journals Development of a Breast Cancer Treatment Program in Port-au-Prince, Haiti: Experiences From the Field

2016 ◽  
Vol 2 (1) ◽  
pp. 9-14 ◽  
Author(s):  
Vincent DeGennaro ◽  
Rachel Libby ◽  
Elizabeth Patberg ◽  
Dieudina Gabriel ◽  
Samer Al-Quran ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Treatment ◽  
Treatment Program ◽  
Medical Training ◽  
Low Cost ◽  
Breast Cancer Treatment ◽  
Outcome Data ◽  
Lessons Learned ◽  
Chemotherapy Drugs ◽  
Treatment Regimens

Purpose The nonprofit Project Medishare launched a breast cancer treatment program in Port-au-Prince in July 2013 to address the demand for breast cancer care in Haiti. We outline the development of the program, highlight specific challenges, and discuss key considerations for others working in global oncology. Methods We reflected on our experiences in the key areas of developing partnerships, building laboratory capacity, conducting medical training, using treatment algorithms, and ensuring access to safe, low-cost chemotherapy drugs. We also critically reviewed our costs and quality measures. Results The program has treated a total of 139 patients with breast cancer with strong adherence to treatment regimens in 85% of patients. In 273 chemotherapy administrations, no serious exposure or adverse safety events were reported by staff. The mortality rate for 94 patients for whom we have complete data was 24% with a median survival time of 53 months. Our outcome data were likely influenced by stage at presentation, with more than half of patients presenting more than 12 months after first noticing a tumor. Future efforts will therefore focus on continuing to improve the level of care, while working with local partners to spread awareness, increase screening, and get more women into care earlier in the course of their disease. Conclusion Our experiences may inform others working to implement protocol-based cancer treatment programs in resource-poor settings and can provide valuable lessons learned for future global oncology efforts.

PPARγ Agonists in Combination Cancer Therapies

2020 ◽  
Vol 20 (3) ◽  
pp. 197-215
Author(s):  
Piotr Mrowka ◽  
Eliza Glodkowska-Mrowka
Keyword(s):  
Targeted Therapy ◽  
Therapeutic Potential ◽  
Pharmacological Therapy ◽  
Treatment Modalities ◽  
Peroxisome Proliferator ◽  
Tumoricidal Activity ◽  
Peroxisome Proliferator Activated Receptor ◽  
Anticancer Efficacy ◽  
Pparγ Agonists

: Peroxisome proliferator-activated receptor-gamma (PPARγ) is a nuclear receptor acting as a transcription factor involved in the regulation of energy metabolism, cell cycle, cell differentiation, and apoptosis. These unique properties constitute a strong therapeutic potential that place PPARγ agonists as one of the most interesting and widely studied anticancer molecules. : Although PPARγ agonists exert significant, antiproliferative and tumoricidal activity in vitro, their anticancer efficacy in animal models is ambiguous, and their effectiveness in clinical trials in monotherapy is unsatisfactory. However, due to pleiotropic effects of PPARγ activation in normal and tumor cells, PPARγ ligands interact with many antitumor treatment modalities and synergistically potentiate their effectiveness. The most spectacular example is a combination of PPARγ ligands with tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML). In this setting, PPARγ activation sensitizes leukemic stem cells, resistant to any previous form of treatment, to targeted therapy. Thus, this combination is believed to be the first pharmacological therapy able to cure CML patients. : Within the last decade, a significant body of data confirming the benefits of the addition of PPARγ ligands to various antitumor therapies, including chemotherapy, hormonotherapy, targeted therapy, and immunotherapy, has been published. Although the majority of these studies have been carried out in vitro or animal tumor models, a few successful attempts to introduce PPARγ ligands into anticancer therapy in humans have been recently made. In this review, we aim to summarize shines and shadows of targeting PPARγ in antitumor therapies.

Sign in / Sign up

Export Citation Format

Share Document